logo
Plus   Neg
Share
Email

KEMET Prices $110 Mln Of Senior Notes

KEMET Corp. (KEM) said Thursday that it has priced an offering of $110 million of aggregate principal amount of 10-1/2% senior notes due 2018.

This represents an increase of $10 million from the initial offering terms announced earlier Thursday. The Senior Notes are priced at 105.5% on a principal amount of $110 million plus accrued interest from November 1, 2011.

The sale of the senior notes is expected to be completed on or about March 27.

KEMET plans to use the net proceeds from the sale of the senior notes to finance a portion of the acquisition of Niotan Inc., make the initial payment to acquire a portion of NEC TOKIN Corp., pay related transactions fees and expenses and for general corporate purposes.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
RELATED NEWS
Trade KEM now with 
Follow RTT